Andrew D. Goldberg is Director at Tarsus Pharmaceuticals, Inc. (TARS). They have made 1 open-market trade across 1 company since 2023, most recently 2026-06-12.
CIK 0001827722
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $19K since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TARS | 19,654 | $1.3M |
Shares reported on the most recent Form 4, priced at the 2026-06-16 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TARS | BUY | 2023-12-15 | 2023-12-19 | $18.96 | $19K | +2.6% | +16.3% | +55.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.